PCSK9 inhibition with a novel fusion protein Oral PCSK9 inhibition: Clinical update VICTORION-INITIATE supports early inclisiran treatment in ASCVD LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD US patients missing out on bempedoic acid Evolocumab benefits in patients with autoimmune and inflammatory diseases

Steve Humphries Articles

Verve-101: Where are we up to with PCSK9 gene editing?

VERVE-101 is a novel CRISPR base editing agent designed to knock out expression of the PCSK9 gene by changing a single DNA base, thereby turning off PCSK9 protein production in hepatocytes and lowering LDL-C. VERVE-101 consists of an mRNA for an adenine base editor and…

Posted on 14 December 2023 | Posted by Steve Humphries | Posted in Expert views, Videos

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters